# EAST Search History

| Ref # | Hits | Search Query | DBs | Default Operator | Plurals | Time Stamp |
|---|---|---|---|---|---|---|
| L1 | 1305 | (514/312).CCLS. | USPAT; USOCR | OR | OFF | 2006/08/03 10:36 |
| L2 | 6291 | quinolin | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:35 |
| L3 | 321 | l1 and l2 | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:35 |
| L4 | 135547 | cancer | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:36 |
| L5 | 83 | l4 and l3 | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:36 |
| L6 | 1887 | (514/312).CCLS. | US-PGPUB; USPAT; USOCR | OR | OFF | 2006/08/03 10:37 |
| L7 | 500 | l6 and l2 | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:37 |
| L8 | 169 | l7 and l4 | US-PGPUB; USPAT | OR | OFF | 2006/08/03 10:37 |

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:517333 CAPLUS
DOCUMENT NUMBER: 141:207124
TITLE: Streamlined Processes for the Synthesis of a Farnesyl Transferase Inhibitor Drug Candidate
AUTHOR(S): Andresen, Brian M.; Couturier, Michel; Cronin, Brian; D'Occhio, Michael; Ewing, Marcus D.; Guinn, Mark; Hawkins, Joel M.; Jasys, V. John; LaGreca, Susan D.; Lyssikatos, Joseph P.; Moraski, Garrett; Ng, Karl; Raggon, Jeffrey W.; Stewart, A. Morgan; Tickner, Derek L.; Tucker, John L.; Urban, Frank J.; Vazquez, Enrique; Wei, Lulin
CORPORATE SOURCE: Pfizer Inc., Groton, CT, 06340, USA
SOURCE: Organic Process Research & Development (2004), 8(4), 643-650
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:207124
IT 260050-75-7P 439153-65-8P
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 6-[(4-chlorophenyl)hydroxy(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one, a farnesyl transferase inhibitor drug candidate)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 439153-65-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate, hydrate (2:2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).




CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.




IT 439153-66-9P
RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)
(preparation of 6-[(4-chlorophenyl)hydroxy(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one, a farnesyl transferase inhibitor drug candidate)
RN 439153-66-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:777730 CAPLUS
DOCUMENT NUMBER: 137:299915
TITLE: Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition for the treatment of cancer
INVENTOR(S): Kajiji, Shama M.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 36 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|
| WO 2002078706 | A1 | 20021010 | WO 2002-US9751 | 20020329 |

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2002151563 A1 20021017 US 2002-103251 20020321
PRIORITY APPLN. INFO.: US 2001-279965P P 20010329
OTHER SOURCE(S): MARPAT 137:299915
IT 260050-75-7 260050-76-8
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition for the treatment of cancer)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:487550 CAPLUS
DOCUMENT NUMBER: 137:63258
TITLE: Crystal forms and production method of 6-[(4-chlorophenyl)(hydroxy)(3-methyl-3H-imidazol-4-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-1H-quinolin-2-one 2,3-dihydroxybutanedioate salts
INVENTOR(S): Li, Zheng Jane; Lyssikatos, Joseph Peter; Meltz, Clifford Nathaniel; Newton, Linda Sue; Tickner, Derek Lawrence
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | | DATE |
|---|---|---|---|---|---|
| WO 2002050058 | A1 | 20020627 | WO 2001-IB2299 | | 20011203 |
| WO 2002050058 | C1 | 20030220 | | | |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| CA 2432137 | AA | 20020627 | CA 2001-2432137 | | 20011203 |
| AU 2002018436 | A5 | 20020701 | AU 2002-18436 | | 20011203 |
| BR 2001016302 | A | 20040113 | BR 2001-16302 | | 20011203 |
| EP 1395577 | A1 | 20040310 | EP 2001-271105 | | 20011203 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR | | | | | |
| JP 2004516287 | T2 | 20040603 | JP 2002-551554 | | 20011203 |
| US 2003032653 | A1 | 20030213 | US 2001-21201 | | 20011207 |
| US 6645982 | B2 | 20031111 | | | |
| US 2003212103 | A1 | 20031113 | US 2003-441567 | | 20030520 |
| US 6734308 | B2 | 20040511 | | | |
| US 2005020836 | A1 | 20050127 | US 2004-801471 | | 20040315 |

PRIORITY APPLN. INFO.:

| | | |
|---|---|---|
| US 2000-256598P | P | 20001219 |
| WO 2001-IB2299 | W | 20011203 |
| US 2001-21201 | A3 | 20011207 |
| US 2003-441567 | A3 | 20030520 |

IT 439153-64-7P
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(HPLC chiral resolution; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl]1(ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)
RN 439153-64-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl- (9CI) (CA INDEX NAME)



IT 439153-67-0P 439153-68-1P 439153-69-2P
439153-70-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl](ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)

RN 439153-67-0 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-76-8
CMF C29 H22 Cl N3 O2

Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 439153-68-1 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 439153-64-7
CMF C29 H22 Cl N3 O2



CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.



RN 439153-69-2 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, rel-(2R,3R)-2,3-dihydroxybutanedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 439153-64-7
CMF C29 H22 Cl N3 O2



CM 2

CRN 133-37-9
CMF C4 H6 O6

Relative stereochemistry.



RN 439153-70-5 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)-, (2R,3R)-2,3-dihydroxybutanedioate (1:1), hydrate (9CI) (CA INDEX NAME)

CM 1

CRN 260050-76-8
CMF C29 H22 Cl N3 O2

Rotation (-).



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



IT 439153-65-8P 439153-66-9P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(crystal structure; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl]1(ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)

RN 439153-65-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate, hydrate (2:2:3) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



RN 439153-66-9 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 260050-75-7
CMF C29 H22 Cl N3 O2

Rotation (+).



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.



IT 260050-75-7P 260050-76-8P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(separation of enantiomers; crystal forms and preparation of [(chlorophenyl)(hydroxy)(imidazolyl)methyl]1(ethynylphenyl)quinolinone derivative tartrate salts and pharmaceutical compns. for treatment of hyperproliferative diseases)
RN 260050-75-7 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-

yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:161277 CAPLUS
DOCUMENT NUMBER: 132:194300
TITLE: Preparation of alkynyl-substituted quinolin-2-ones as anticancer agents
INVENTOR(S): La Greca, Susan Deborah; Lyssikatos, Joseph Peter
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|---|---|---|---|---|

Published

| | | | | | |
|---|---|---|---|---|---|
| WO 2000012499 | | A1 | 20000309 | WO 1999-IB1398 | 19990806 |
| W: | AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW | | | | |
| RW: | GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG | | | | |
| CA 2341690 | | AA | 20000309 | CA 1999-2341690 | 19990806 |
| AU 9949254 | | A1 | 20000321 | AU 1999-49254 | 19990806 |
| BR 9913138 | | A | 20010508 | BR 1999-13138 | 19990806 |
| EP 1107963 | | A1 | 20010620 | EP 1999-933084 | 19990806 |
| EP 1107963 | | B1 | 20060322 | | |
| R: | AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY | | | | |
| TR 200101343 | | T2 | 20010921 | TR 2001-200101343 | 19990806 |
| EE 200100118 | | A | 20020617 | EE 2001-118 | 19990806 |
| JP 2002523504 | | T2 | 20020730 | JP 2000-567527 | 19990806 |
| JP 3495706 | | B2 | 20040209 | | |
| NZ 509372 | | A | 20030829 | NZ 1999-509372 | 19990806 |
| AT 321037 | | E | 20060415 | AT 1999-933084 | 19990806 |
| US 6150377 | | A | 20001121 | US 1999-383755 | 19990826 |
| US 6294552 | | B1 | 20010925 | US 2000-628039 | 20000727 |
| ZA 2001001173 | | A | 20020412 | ZA 2001-1173 | 20010212 |
| NO 2001000964 | | A | 20010426 | NO 2001-964 | 20010226 |
| HR 2001000142 | | A1 | 20020228 | HR 2001-142 | 20010227 |
| BG 105365 | | A | 20011130 | BG 2001-105365 | 20010320 |
| US 2002128287 | | A1 | 20020912 | US 2001-900401 | 20010706 |
| US 6579887 | | B2 | 20030617 | | |

| | | |
|---|---|---|
| PRIORITY APPLN. INFO.: | US 1998-98145P | P 19980827 |
| | WO 1999-IB1398 | W 19990806 |
| | US 1999-383755 | A3 19990826 |
| | US 2000-628039 | A3 20000727 |

OTHER SOURCE(S): MARPAT 132:194300

IT 260050-75-7P 260050-76-8P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of alkynyl-substituted quinolin-2-ones as anticancer agents)

RN 260050-75-7 CAPLUS

CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 260050-76-8 CAPLUS
CN 2(1H)-Quinolinone, 6-[(4-chlorophenyl)hydroxy(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-ethynylphenyl)-1-methyl-, (-)- (9CI) (CA INDEX NAME)

Rotation (-).




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT